NO20013751L - Purininhibitorer av cyklinavhengig kinase 2 og IkB-<alfa> - Google Patents

Purininhibitorer av cyklinavhengig kinase 2 og IkB-<alfa>

Info

Publication number
NO20013751L
NO20013751L NO20013751A NO20013751A NO20013751L NO 20013751 L NO20013751 L NO 20013751L NO 20013751 A NO20013751 A NO 20013751A NO 20013751 A NO20013751 A NO 20013751A NO 20013751 L NO20013751 L NO 20013751L
Authority
NO
Norway
Prior art keywords
ikb
cyclin
alfa
dependent kinase
purine inhibitors
Prior art date
Application number
NO20013751A
Other languages
English (en)
Other versions
NO20013751D0 (no
NO327776B1 (no
Inventor
Robert T Lum
Cheri Lynn Blum
Richard Mackman
Michael M Wick
Steven R Schow
Jeffrey A Zablocki
Prabha Ibrahim
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20013751D0 publication Critical patent/NO20013751D0/no
Publication of NO20013751L publication Critical patent/NO20013751L/no
Publication of NO327776B1 publication Critical patent/NO327776B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En 2,6,9-trisubstituert purinforbindelse som er anvendbar for inhibering av celleproliferasjonsforstyrrelser og som antisoppmiddel.
NO20013751A 1999-02-01 2001-07-31 Utvalgte 2,6,9-trisubstituerte purinforbindelser, farmasoytisk preparat omfattende slike og anvendelse for fremstilling av antifugale midler og farmasoytiske preparater for inhibering av celleproliferasjon NO327776B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24122499A 1999-02-01 1999-02-01
PCT/US2000/001407 WO2000044750A1 (en) 1999-02-01 2000-01-20 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)

Publications (3)

Publication Number Publication Date
NO20013751D0 NO20013751D0 (no) 2001-07-31
NO20013751L true NO20013751L (no) 2001-09-27
NO327776B1 NO327776B1 (no) 2009-09-21

Family

ID=22909777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013751A NO327776B1 (no) 1999-02-01 2001-07-31 Utvalgte 2,6,9-trisubstituerte purinforbindelser, farmasoytisk preparat omfattende slike og anvendelse for fremstilling av antifugale midler og farmasoytiske preparater for inhibering av celleproliferasjon

Country Status (26)

Country Link
EP (1) EP1150982B1 (no)
JP (1) JP3681984B2 (no)
KR (1) KR20010093308A (no)
CN (1) CN1353713A (no)
AR (1) AR029612A1 (no)
AT (1) ATE306487T1 (no)
AU (1) AU2969300A (no)
BR (1) BR0007919A (no)
CA (1) CA2361518A1 (no)
CZ (1) CZ20012765A3 (no)
DE (1) DE60023268T2 (no)
DK (1) DK1150982T3 (no)
ES (1) ES2246829T3 (no)
GE (1) GEP20033092B (no)
HK (1) HK1044334A1 (no)
HU (1) HUP0200535A3 (no)
IL (2) IL144675A0 (no)
MX (1) MXPA01007851A (no)
NO (1) NO327776B1 (no)
NZ (1) NZ513371A (no)
PL (1) PL350001A1 (no)
RU (1) RU2001124352A (no)
TR (1) TR200102714T2 (no)
TW (1) TW538044B (no)
UA (1) UA74142C2 (no)
WO (1) WO2000044750A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
WO2000012486A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
ATE301123T1 (de) 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US7189730B2 (en) 2001-12-18 2007-03-13 Cv Therapeutics, Inc. A2A adenosine receptor antagonists
DK1492581T3 (da) 2002-02-15 2007-04-30 Cv Therapeutics Inc Polymerbelægning til medicinske anordninger
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
KR20080004550A (ko) 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
JP5108752B2 (ja) * 2005-05-16 2012-12-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 自己免疫疾患を治療するための化合物とそれら化合物の使用
JP4992716B2 (ja) * 2005-08-12 2012-08-08 アステラス製薬株式会社 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法
KR20080049130A (ko) 2005-09-30 2008-06-03 아스트라제네카 아베 세포 증식 억제 활성을 갖는 이미다조 [1,2-ａ] 피리딘
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
RS53494B9 (sr) 2009-06-29 2020-11-30 Incyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
IL299533A (en) 2011-09-02 2023-02-01 Incyte Holdings Corp Heterocycloamines as P13K inhibitors
SG2014014450A (en) 2011-09-22 2014-09-26 Pfizer Pyrrolopyrimidine and purine derivatives
WO2013130461A1 (en) 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CZ306894B6 (cs) * 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
WO2014134750A1 (zh) * 2013-03-08 2014-09-12 中国人民解放军军事医学科学院放射与辐射医学研究所 2,6,9-三取代嘌呤衍生物及其制备方法与应用
JPWO2015005491A1 (ja) * 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA55193B1 (fr) 2015-02-27 2022-10-31 Incyte Holdings Corp Procédés de préparation d'un inhibiteur de pi3k
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107235981B (zh) * 2017-05-25 2019-10-25 北京工业大学 低氧激活o6-苄基-2-硝基嘌呤衍生物及制法和应用
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
CN110256436B (zh) * 2019-06-27 2020-06-09 南京雷正医药科技有限公司 作为Trk激酶抑制剂的嘌呤类化合物
CN117479944A (zh) * 2021-04-02 2024-01-30 泰州亿腾景昂药业股份有限公司 周期蛋白依赖性激酶抑制剂
WO2023046128A1 (en) * 2021-09-27 2023-03-30 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases

Also Published As

Publication number Publication date
EP1150982A1 (en) 2001-11-07
JP2002535405A (ja) 2002-10-22
HK1044334A1 (zh) 2002-10-18
IL144675A0 (en) 2002-05-23
AU2969300A (en) 2000-08-18
IL144675A (en) 2008-11-26
TW538044B (en) 2003-06-21
EP1150982B1 (en) 2005-10-12
TR200102714T2 (tr) 2002-01-21
ATE306487T1 (de) 2005-10-15
UA74142C2 (uk) 2005-11-15
CA2361518A1 (en) 2000-08-03
BR0007919A (pt) 2002-04-09
CN1353713A (zh) 2002-06-12
PL350001A1 (en) 2002-10-21
KR20010093308A (ko) 2001-10-27
MXPA01007851A (es) 2003-06-04
RU2001124352A (ru) 2004-02-20
NO20013751D0 (no) 2001-07-31
HUP0200535A2 (hu) 2002-07-29
NO327776B1 (no) 2009-09-21
HUP0200535A3 (en) 2002-11-28
JP3681984B2 (ja) 2005-08-10
ES2246829T3 (es) 2006-03-01
DE60023268T2 (de) 2006-06-01
DK1150982T3 (da) 2005-12-27
GEP20033092B (en) 2003-10-27
DE60023268D1 (de) 2006-03-02
WO2000044750A1 (en) 2000-08-03
NZ513371A (en) 2003-08-29
CZ20012765A3 (cs) 2002-08-14
AR029612A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
NO20013751L (no) Purininhibitorer av cyklinavhengig kinase 2 og IkB-&lt;alfa&gt;
IL163781A0 (en) Purine derivatives as kinase inhibitors
UA74370C2 (uk) Піроло(2,3-d)піримідинові сполуки як імуносупресори
GB0124933D0 (en) Chemical compounds
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
NO20015650L (no) Pyrrolotriazin-inhibitorer for kinaser
RS20050462A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
AU2003259153A1 (en) Substituted triazine kinase inhibitors
IL163777A0 (en) Kinase inhibitors
TR200101860T2 (tr) Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
BRPI0407841A (pt) inibidores heterocìclicos de quinase
BR0109542A (pt) Derivados de imidazopirina alquilados
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MY128164A (en) Compounds
GB0308201D0 (en) Novel compounds
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
AP2001002045A0 (en) FKBP inhibitors.
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
NO20054289D0 (no) Imiciazo[4,5-b]kinolinderivater og dem anvendelse som NO-syntaseinhibitorer
DK1690853T3 (da) Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees